FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 599 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with... January 22, 2024 A Cancer Revolution: What the experts think of the new Science... July 25, 2022 ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular... August 7, 2024 EMA Recommends Extending Indications for Durvalumab July 17, 2025 Load more HOT NEWS Off Target: Investigating the Abscopal Effect as a Treatment for Cancer Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs FDA Approves Pembrolizumab with Chemotherapy for HER2-negative Gastric or Gastro-Oesophageal Junction... High Risk of BCSM at 20 Years in Men with Hormone...
